Mark Kawakami - Feb 3, 2025 Form 4 Insider Report for Arcadia Biosciences, Inc. (RKDA)

Role
Chief Financial Officer
Signature
Mark Kawakami, by Attorney-in-fact, Solaeta Chan
Stock symbol
RKDA
Transactions as of
Feb 3, 2025
Transactions value $
$1,743
Form type
4
Date filed
2/5/2025, 07:34 PM
Previous filing
Aug 21, 2024
Next filing
May 12, 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RKDA Common Stock Purchase $1.74K +700 +35.34% $2.49 2.68K Feb 3, 2025 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Reflects the purchase of 700 shares of the Issuer's common stock on 2/3/25 at a per share purchase price of $2.49 pursuant to participation in the Issuer's 2015 Employee Stock Purchase Plan ("ESPP"). This transaction is exempt from Rule 16b-3(c). In accordance with the ESPP, these shares were purchased at a price equal to 85% of the closing price of Issuer's common stock.
F2 The amount includes the 2015 Employee Stock Purchase Plan ("ESPP") purchases, for the purchase periods from August 1, 2022 to February 1, 2025. These transactions were exempt from Rule 16b-3(c). In accordance with the ESPP, these shares were purchased at a price equal to 85% of the closing price of Issuer's Common Stock on the respective offering date or purchase date, whichever is lower.